- Home
- TGHL vs ICU Comparison
TGHL vs ICU Comparison
Compare TGHL & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TGHL | ICU |
|---|---|---|
| Founded | 2020 | 2018 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 9.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TGHL | ICU |
|---|---|---|
| Price | $0.35 | $2.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 50.3K | ★ 54.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1,043.70 |
| Revenue Next Year | N/A | $54.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $0.22 |
| 52 Week High | $3.80 | $2.98 |
Technical Indicators
Market Signals| Indicator | TGHL | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 47.42 | 60.15 |
| Support Level | $0.31 | $2.26 |
| Resistance Level | $0.51 | $2.78 |
| Average True Range (ATR) | 0.04 | 0.18 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 28.42 | 61.16 |
Price Performance
Historical ComparisonAbout TGHL The GrowHub Limited Class A Ordinary Shares
The Growhub Ltd operates at the intersection of technology and supply chain management in the food industry, focusing on enhancing product traceability and authenticity. With a commitment to innovation and sustainability, It has developed a multi-faceted approach to address industry challenges. its business currently comprises two main divisions, which are the GrowHub Platform and its product trading facilitation offering.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.